ライフサイエンスコーパス: clindamycin

1 and antagonistic effects in combination with clindamycin.

2 the resistance of streptococcal biofilms to clindamycin.

3 nicillin-allergic patient, which now include clindamycin.

4 s samples, more than 92% were susceptible to clindamycin.

5 nterococcus faecalis and use of linezolid or clindamycin.

6 sses tested or resistant to erythromycin and clindamycin.

7 of the CA-MRSA isolates were susceptible to clindamycin.

8 lanic acid < clarithromycin < penicillin V < clindamycin.

9 th a high proportion of susceptible strains, clindamycin.

10 leads to resistance to erythromycin but not clindamycin.

11 istant, inducibly resistant, or sensitive to clindamycin.

12 rly 5 times less likely to cause an ADR than clindamycin.

13 ores 2 days after receiving a single dose of clindamycin.

14 None were resistant to clindamycin.

15 cherichia coli where it is predicted to bind clindamycin.

16 trong selective advantage in the presence of clindamycin.

17 sion was minimally affected by subinhibitory clindamycin.

18 d the same concentrations of pneumococci and clindamycin.

19 ere constitutively or inducibly resistant to clindamycin.

20 y similar between groups but tended to favor clindamycin.

21 fter combination treatment with fosmidomycin-clindamycin.

22 ions, atovaquone + azithromycin or quinine + clindamycin.

23 resistance to tetracycline, erythromycin and clindamycin.

24 old use of macrolides, fluoroquinolones, and clindamycin.

25 icrog/ml), amphotericin B (2 microg/ml), and clindamycin (1 microg/ml).

26 om each of the three water matrixes revealed clindamycin (1.1 microg/L) in surface water and multiple

27 mupirocin (1.96-log(10) reduction) and oral clindamycin (1.24-log(10) reduction), which are used to

28 (80.8% resistant or intermediate resistant), clindamycin (100% resistant to 2 mug/mL), and metronidaz

29 floxacin (500 mg twice daily for 10 days) or clindamycin (150 mg 4 times daily for 10 days) on the fe

30 cs and the ribosome inhibitors thiostrepton, clindamycin-2-phosphate, and puromycin are the first rep

31 Erythromycin (39.5%) and clindamycin (26.4%) resistance was common.

32 imethoprim-sulfamethoxazole (10 strains) and clindamycin (3 strains).

33 uncomplicated wound infection received oral clindamycin 300 mg 4 times daily or TMP-SMX 320 mg/1600

34 en with one of these signs to receive either clindamycin 300 mg or placebo orally twice daily for 5 d

35 (ie, Nugent score >=4 was treated with oral clindamycin (300 mg twice daily for 5 days) and urinary

36 Adverse events were more frequent with clindamycin (58 of 265 [21.9%]) than with TMP-SMX (29 of

37 RSA isolates, 95 percent were susceptible to clindamycin, 6 percent to erythromycin, 60 percent to fl

38 thereafter) for seven days (40 subjects) or clindamycin (600 mg every 8 hours) and quinine (650 mg e

39 lower concordance for erythromycin (73.9%), clindamycin (65.5%), and trimethoprim-sulfamethoxazole (

40 follows: oxacillin, 82%; erythromycin, 82%; clindamycin, 73%; levofloxacin, 73%; trimethoprim-sulfam

41 antibiotics except erythromycin (92.1%) and clindamycin (89.5%).

42 0% of the strains tested were susceptible to clindamycin, 96% were susceptible to penicillin and ceft

43 for enterotoxin D (74.5%); and resistant to clindamycin (98.6%), erythromycin (99.0%), and levofloxa

44 Clindamycin administration may improve outcomes in patie

45 Clindamycin also reduced adverse outcomes across the ran

46 shunt group), antibiotic-impregnated (0.15% clindamycin and 0.054% rifampicin; antibiotic shunt grou

47 d in an unknown sample and susceptibility to clindamycin and cefoxitin can be ascertained.

48 aureus) and determine its susceptibility to clindamycin and cefoxitin.

49 rains of each species were also resistant to clindamycin and erythromycin and carried the erm(A) (S.

50 -MRSA and HA-MRSA isolates were resistant to clindamycin and erythromycin, but CA-MRSA was more susce

51 these were also constitutively resistant to clindamycin and had the erm(B) gene.

52 Inhibition of nuclease activity by clindamycin and immunoglobulin enhanced S. aureus cleara

53 lated with healthy human feces, treated with clindamycin and infected with C difficile with the addit

54 Emerging treatments for strep TSS include clindamycin and intravenous gamma-globulin.

55 The use of clindamycin and intravenous immunoglobulin (IVIG) in tre

56 r differences in the susceptibility rates to clindamycin and levofloxacin according to patient age gr

57 In contrast, susceptibility rates to clindamycin and levofloxacin varied from 94.0% and 60.7%

58 ed >/= 65 years, whereas resistance rates to clindamycin and levofloxacin were lowest among isolates

59 In contrast, clindamycin and linezolid markedly suppressed translatio

60 anslation inhibitors (such as tetracyclines, clindamycin and macrolides) and gyrase inhibitors (such

61 ator-associated pneumonia (VAP) who received clindamycin and piperacillin-tazobactam as part of their

62 In this study the antibiotic clindamycin and polyphenol extracts from pomegranate and

63 mpared with 72 percent of those who received clindamycin and quinine (P<0.001).

64 romycin and 73 percent of those who received clindamycin and quinine (P=0.66), and after six months n

65 azithromycin is as effective as a regimen of clindamycin and quinine and is associated with fewer adv

66 unosuppressive therapy and administration of clindamycin and quinine antimicrobials.

67 A course of clindamycin and quinine is the standard treatment, but t

68 sh (each in 8 percent of the subjects); with clindamycin and quinine the most common adverse effects

69 Antibiotic treatment with combinations of clindamycin and rifampicin, or ertapenem followed by com

70 The association between clindamycin and shorter duration of colonization after M

71 nce of the CC5 clone in 2010 with associated clindamycin and tetracycline resistance.

72 and 13.0% of the isolates were resistant to clindamycin and tetracycline, respectively.

73 wo days later, they were given injections of clindamycin and then challenged 1 day later with differe

74 Il10(-/-) mice were gavaged with antibiotic clindamycin and then infected with Cj-P0, Cj-P1, or Cj-P

75 In settings where MRSA is prevalent, clindamycin and TMP-SMX produce similar cure and adverse

76 We found no significant difference between clindamycin and TMP-SMX, with respect to either efficacy

77 Clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX)

78 nd 62% and 36% of isolates were resistant to clindamycin and trimethoprim/sulfamethoxazole, respectiv

79 Clindamycin and vasopressor intensity were higher among

80 4% were susceptible to doxycycline, 29.7% to clindamycin, and 21.6% to trimethoprim-sulfamethoxazole.

81 the ketolide telithromycin, the lincosamide clindamycin, and a phenicol, chloramphenicol, at resolut

82 ribosome-targeting antibiotics: tobramycin, clindamycin, and chloramphenicol.

83 more likely to be sensitive to erythromycin, clindamycin, and ciprofloxacin.

84 es that were susceptible to chloramphenicol, clindamycin, and erythromycin were lower in 2003 and 200

85 so-called 4C (cephalosporins, co-amoxiclav, clindamycin, and fluoroquinolones) and macrolide antibio

86 igh MICs for erythromycin, azithromycin, and clindamycin, and intermediate to high MICs for moxifloxa

87 Penicillin, clindamycin, and intravenous immune globulin (Venoglobul

88 n general, resistance rates to erythromycin, clindamycin, and levofloxacin were higher in the populat

89 Tetracycline, erythromycin, clindamycin, and metronidazole revealed poor in vitro ac

90 Cephalosporins, clindamycin, and radio contrast media (RCM) were mainly

91 ing intravenous ciprofloxacin, rifampin, and clindamycin, and supportive therapy appears to have slow

92 xacin, norfloxacin, aztreonam, erythromycin, clindamycin, and trimethoprim-sulfamethoxazole.

93 ed with significantly more fluoroquinolones, clindamycin, and vancomycin (P < .0001) for each antibio

94 s (1 mug/ml + 0.25 mug/ml [erythromycin plus clindamycin] and 1 mug/ml + 0.5 mug/ml) with three diffe

95 Our model recapitulates known dynamics of clindamycin antibiotic treatment and C. difficile infect

96 s in the context of a critical health issue: clindamycin antibiotic treatment and opportunistic Clost

97 and azithromycin) and lincosamide (including clindamycin) antibiotics are recommended for treatment o

98 quinine plus tetracycline or doxycycline or clindamycin are the best treatment options.

99 especially beta-lactam antibiotics, RCM and clindamycin, are common elicitors of subsequent DHR in p

100 antibiotic therapy with benzylpenicillin and clindamycin as seen in this case is essential for patien

101 for susceptibility to amoxicillin at 8 mg/L, clindamycin at 4 mg/L, doxycycline at 4 mg/L, and metron

102 esistance of S. pyogenes to erythromycin and clindamycin at an urban tertiary-care hospital.

103 ponsible; remarkably, however, subinhibitory clindamycin blocked production of several of the individ

104 the respiratory tract for susceptibility to clindamycin by agar disk diffusion is an easy and inexpe

105 Resistance to clindamycin by bacterial vaginosis-associated anaerobic

106 four combinations of erythromycin (ERY) and clindamycin (CC) (ERY and CC at 4 and 0.5, 6 and 1, 8 an

107 lity testing with amoxicillin, azithromycin, clindamycin, ciprofloxacin, and doxycycline on blood-sup

108 g treatment for four of the six antibiotics (clindamycin, ciprofloxacin, penicillin-G, and trimethopr

109 oth microdilution (BMD) were used to perform clindamycin (CLI) induction testing on 128 selected nond

110 Addition of clindamycin (CLI) is recommended, although clinical evid

111 fepime, cefotaxime (CTX), ceftriaxone (CTR), clindamycin (CLI), erythromycin (ERY), gatifloxacin, lev

112 xigenic C. difficile after administration of clindamycin (Cm).

113 the use of 4C antibiotics (fluoroquinolones, clindamycin, co-amoxiclav, and cephalosporins) and other

114 The sensitivity of the erythromycin plus clindamycin combination of 1 mug/ml + 0.25 mug/ml was 91

115 synergy with Clarithromycin, Doxycycline and Clindamycin, combinations of which were taken forward fo

116 reater numbers under selective pressure from clindamycin, compared with a control strain.

117 tudy assessed two different erythromycin and clindamycin concentration combinations in single wells (

118 ion test (D-zone test) with erythromycin and clindamycin disks and a single-well broth test combining

119 Simple placement of erythromycin and clindamycin disks at a distance achieved with a standard

120 and children to evaluate whether 2-microgram clindamycin disks can distinguish between isolates manif

121 the reliability of placing erythromycin and clindamycin disks in adjacent positions (26 to 28 mm apa

122 tilize closely approximated erythromycin and clindamycin disks; the flattening of the clindamycin zon

123 inal flora and bacterial vaginosis with oral clindamycin early in the second trimester significantly

124 y testing revealed over 100-fold increase of clindamycin EC(50) in strains harboring one of these mut

125 sk diffusion D-zone test and an erythromycin-clindamycin (ERY + CLI) single-well broth test for induc

126 This study assessed an erythromycin-clindamycin (ERY-CC) broth test for inducible CC resista

127 greater resistance than SCCmec-IV strains to clindamycin, erythromycin, levofloxacin, gentamicin, rif

128 mycin-resistant isolates were susceptible to clindamycin even upon induction with erythromycin and ha

129 and primary-case use of fluoroquinolones and clindamycin exceeding total use thresholds.

130 ach strain, 10 hamsters were given 1 dose of clindamycin, followed 5 days later with 100 C. difficile

131 10 hamsters per strain were given 1 dose of clindamycin, followed 5 days later with gastric inoculat

132 ycin monotherapy vs combination therapy with clindamycin for ABSSSIs.

133 e-well broth test combining erythromycin and clindamycin for detection of inducible clindamycin resis

134 recommends prompt diagnosis and quinine plus clindamycin for treatment of uncomplicated malaria in th

135 n the variability of inducible resistance to clindamycin found in our two hospitals, we conclude that

136 mutant ribosomes resistant to the antibiotic clindamycin from a library of ~4 x 10(3) rRNA variants.

137 MSSA became more resistant to ciprofloxacin, clindamycin, gentamicin sulfate, and trimethoprim-sulfam

138 ased antibiotic resistance to ciprofloxacin, clindamycin, gentamicin, and trimethoprim-sulfamethoxazo

139 1 month of follow-up were less common in the clindamycin group (15 of 221, 6.8%) than in the TMP-SMX

140 al of 524 patients were enrolled (264 in the clindamycin group and 260 in the TMP-SMX group), includi

141 intention-to-treat population (80.3% in the clindamycin group and 77.7% in the TMP-SMX group; differ

142 uld be evaluated (466 patients; 89.5% in the clindamycin group and 88.2% in the TMP-SMX group; differ

143 The clindamycin group had a significantly lower rate of recu

144 ion, the cure rate among participants in the clindamycin group was similar to that in the TMP-SMX gro

145 Exposure to ciprofloxacin or clindamycin had a strong effect on the diversity of the

146 Women receiving clindamycin had significantly fewer miscarriages or pret

147 In particular, clindamycin had the highest rate of fatal and nonfatal A

148 the pyrosequencing results, it appears that clindamycin has more impact than ciprofloxacin on the in

149 nolone plus amoxicillin/clavulanate (or plus clindamycin if penicillin allergic) is recommended as em

150 n the adult samples, 50% were susceptible to clindamycin in 2003 and 2004, whereas greater than 75% w

151 dilution test incorporating erythromycin and clindamycin in combination is a sensitive and specific i

152 This mutant was highly resistant to clindamycin in in vitro translation reactions and yet wa

153 ccus hominis isolate, six VMEs for inducible clindamycin in S. aureus isolates, and two major errors

154 hat apicoplast translation is the target for clindamycin in Toxoplasma.

155 doxycycline, amoxicillin, metronidazole, or clindamycin, in 55%, 43.3%, 30.3%, and 26.5% of the pati

156 oli) rendered assembled subunits tolerant to clindamycin inhibition.

157 nfidence interval (CI) [1.2, 1.7]; p<0.001), clindamycin (IRR 7.6; 95% CI [2.2, 32.4]; p=0.001), aztr

158 nfidence interval {CI}, 1.2-1.7]; P < .001), clindamycin (IRR, 7.6 [95% CI, 2.2-32.4]; P = .001), and

159 The use of clindamycin is a specific risk factor for diarrhea due t

160 n-contaminated surgeries, which suggest that clindamycin is an inadequate prophylactic antibiotic the

161 with vancomycin, tobramycin, meropenem, and clindamycin is described.

162 Clindamycin is increasingly used to treat canine pyoderm

163 e resistance to vaginal anaerobic flora when clindamycin is used as treatment.

164 subset of CA-MRSA could be problematic when clindamycin is used.

165 days) and were equally randomized to vaginal clindamycin, lactobacillus-vaginal probiotic or vaginal

166 inhibitors of prokaryotic translation (e.g. clindamycin, macrolides and tetracyclines).

167 We show that a single dose of clindamycin markedly reduces the diversity of the intest

168 tes of MRSA abscesses with susceptibility to clindamycin may reflect the high prevalence level of CAM

169 eatment was initiated with benzylpenicillin, clindamycin, metronidazole and vancomycin.

170 n reported with amoxicillin/clavulanic acid, clindamycin, metronidazole, and the combination therapy

171 Erythromycin and clindamycin MICs were related to the presence of ermA, e

172 ll ermB(+) isolates were highly resistant to clindamycin (MICs >256 microgram/ml), whereas all mefE(+

173 ml), ciprofloxacin (MICs, <or= 1 microg/ml), clindamycin (MICs, <or=0.5 microg/ml), rifampin (MICs, <

174 actors for a fulminant case were exposure to clindamycin (odds ratio [OR]: 1.23, P = .01) or proton p

175 However, 55% of the isolates had MICs to clindamycin of >0.25 mug/ml, 44% had MICs to erythromyci

176 ceptibilities to penicillin, macrolides, and clindamycin of 1,655 invasive isolates of Streptococcus

177 responsible for the effects of subinhibitory clindamycin on the overall exoprotein pattern.

178 mpicillin or the protein synthesis inhibitor clindamycin or azithromycin.

179 tected in samples containing the antibiotics clindamycin or cefoxitin, the sample is deemed to be res

180 f BV were randomized to receive intravaginal clindamycin or metronidazole.

181 Exposure to either clindamycin or polyphenols led to the loss of colonizati

182 hat had received treatment with subcutaneous clindamycin or saline.

183 s compared with incision and drainage alone, clindamycin or TMP-SMX in conjunction with incision and

184 ly assigned in a 1:1 ratio to receive either clindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) f

185 n high numbers under selective pressure from clindamycin or vancomycin, compared with control strains

186 y Score II (odds ratio [OR], 1.1; P = .007), clindamycin (OR, 8.6; P = .007), and IVIG (OR, 5.6; P =

187 -effectiveness of antibiotic (rifampicin and clindamycin) or silver shunts compared with standard shu

188 fotetan (P = 0.006), cephalothin (P<0.0001), clindamycin (P = 0.04), erythromycin (P<0.0001), methici

189 nonsusceptible to penicillin, erythromycin, clindamycin, penicillin plus erythromycin, and multiple

190 reated patients (0.31; 95% CI, .09-1.12) and clindamycin plus IVIG-treated patients (0.12; 95% CI, .0

191 tiple case reports, a 7- to 10-day course of clindamycin plus quinine is often used to treat severe b

192 Clindamycin predisposes patients to C. difficile colitis

193 ACT, which were given for 3 days, or quinine-clindamycin (QnC), which was given for 5-7 days, followi

194 prevalence of MLSBi among CA-MRSA isolates, clindamycin remains a useful option for outpatient thera

195 erythromycin (86.7% to 78.4%, P = .036) and clindamycin resistance (84.3% to 47.9%, P < .001) and a

196 High prevalence of clindamycin resistance (96.2%) was unexpected.

197 id resistance (fusC) (n = 181), erythromycin/clindamycin resistance (ermC) (n = 132) and gentamicin r

198 us (MRSA) (n = 58), S. aureus with inducible clindamycin resistance (ICR) (n = 30), trimethoprim-sulf

199 ana were performing the D test for inducible clindamycin resistance according to guidelines recommend

200 interval, 1.07-3.01), as was the presence of clindamycin resistance among beta-hemolytic streptococci

201 ensitive and specific indicator of inducible clindamycin resistance and could be included in routine

202 This lineage was commonly associated with clindamycin resistance and, less frequently, tetracyclin

203 The incidences of inducible clindamycin resistance at two hospitals (an inner-city h

204 broth microdilution, examined for inducible clindamycin resistance by D-test, and screened for heter

205 rmedius isolates were positive for inducible clindamycin resistance by double-disk diffusion testing

206 on tests were performed to examine inducible clindamycin resistance by erythromycin induction on both

207 ution method, they were tested for inducible clindamycin resistance by the D-test, and they were scre

208 Constitutive or inducible clindamycin resistance can occur in beta-hemolytic strep

209 hat are close to known mutations that confer clindamycin resistance in other species, but which were

210 This study has shown that inducible clindamycin resistance in staphylococci can be detected

211 n and clindamycin for detection of inducible clindamycin resistance in staphylococci, but only a disk

212 ntrol strains for the detection of inducible clindamycin resistance in staphylococci.

213 3%) were resistant to metronidazole, whereas clindamycin resistance increased significantly for P. bi

214 However, clindamycin resistance is growing worldwide, and resista

215 duced peptidyl transferase activity, whereas clindamycin resistance mutation A2084G (A2058G in E. col

216 hromycin resistance rate and a 60% inducible clindamycin resistance rate but were highly susceptible

217 staphylococci (30.6 to 94.1%) with inducible clindamycin resistance rates of 26.0% and 55.0% for oxac

218 4%) were resistant to erythromycin, and high clindamycin resistance rates were observed (28.5% consti

219 Clindamycin resistance remained low until 2003-2004, whe

220 ly prevalent in NSTIs, and in our population clindamycin resistance was more common than previously d

221 beta-Hemolytic streptococci grew in 31%, and clindamycin resistance was observed in 31% of cultures.

222 d ermA or ermC, 57 demonstrated constitutive clindamycin resistance, and 25 demonstrated inducible re

223 ility testing should be tested for inducible clindamycin resistance.

224 lure of clindamycin therapy due to inducible clindamycin resistance.

225 the positive control organism for inducible clindamycin resistance.

226 (ClnR-4 and ClnR-21) with strong and stable clindamycin resistance.

227 l), 12/158 isolates tested were resistant to clindamycin (resistance breakpoint >/= 8 mug/ml), 10/247

228 s were erythromycin resistant, and 6.9% were clindamycin resistant.

229 No isolate was clindamycin resistant.

230 The emergence of clindamycin-resistant anaerobic gram-negative rods follo

231 e presence of beta-hemolytic streptococci or clindamycin-resistant beta-hemolytic streptococci were c

232 We identified 12 erythromycin- and clindamycin-resistant emm 90 group A streptococcus (GAS)

233 ) to have nasal colonization than those with clindamycin-resistant MRSA infections (71%; P = 0.042).

234 This evidence of clindamycin-resistant parasites in the Amazon suggests t

235 y related, tetracycline-, erythromycin-, and clindamycin-resistant sequence type 459 (ST459) strains

236 (ST)459, a tetracycline-, erythromycin-, and clindamycin-resistant ST first identified in Minnesota,

237 ith beta-hemolytic streptococci-particularly clindamycin-resistant strains-may portend a more locally

238 Clindamycin-resistant subpopulations of P. bivia and bla

239 and inducible or constitutive resistance to clindamycin, respectively, whereas expression of the mef

240 % and 15% were resistant to erythromycin and clindamycin, respectively.

241 In this report, we show that subinhibitory clindamycin (SBCL) eliminates production of nearly all e

242 eports, however, we found that subinhibitory clindamycin stimulates synthesis of coagulase and fibron

243 fficile infection at least 10 days following clindamycin, suggesting that resolution of diarrhea and

244 We examined erythromycin and clindamycin susceptibilities with Etest methodology amon

245 isolates that are erythromycin resistant but clindamycin susceptible by in vitro antimicrobial suscep

246 overed from these patients, 166 (41.1%) were clindamycin susceptible, 190 (47.0%) carried staphylococ

247 methoxazole (TMP-SMX), and all isolates were clindamycin susceptible.

248 tion on both CA and hospital-associated (HA) clindamycin-susceptible and erythromycin-resistant isola

249 Patients with clindamycin-susceptible MRSA infections were less likely

250 rapy even among women colonized initially by clindamycin-susceptible strains.

251 CA-MRSA isolates, that is, isolates that are clindamycin-susceptible, PVL+, ST8, and/or contain SCCme

252 The clindamycin, tetracycline, and mupirocin resistance gene

253 nizing isolates to penicillin, erythromycin, clindamycin, tetracycline, and other antimicrobial agent

254 ents (penicillin, methicillin, erythromycin, clindamycin, tetracycline, ciprofloxacin, vancomycin, tr

255 Individual or multiple resistance to clindamycin, tetracycline, erythromycin, levofloxacin, o

256 978 through 1983), the most common cause was clindamycin, the standard diagnostic test was the cytoto

257 TSS patients demonstrates that both IVIG and clindamycin therapy contribute to a significantly improv

258 We report a case of failure of clindamycin therapy due to inducible clindamycin resista

259 be made in health policy away from quinine + clindamycin therapy for malaria in pregnant women and in

260 ficantly worse (survival rate, 56%) than (1) clindamycin therapy used either alone (82%) or in combin

261 obic gram-negative rods persisting following clindamycin therapy.

262 addition of the protein synthesis inhibitor clindamycin to S. aureus LAC cultures decreased nuc1 tra

263 dual antimicrobial agents ranged from 90.4% (clindamycin) to 100% (vancomycin and gatifloxacin).

264 was cured at 7-14 days in 187 of 203 (92.1%) clindamycin-treated and 182 of 198 (91.9%) TMP-SMX-treat

265 After orogastric inoculation of VRE, clindamycin-treated mice acquired high concentrations of

266 to high concentrations in cecal contents of clindamycin-treated mice and in cecal mucus of both grou

267 Inoculation of clindamycin-treated mice with C. difficile (VPI 10463) s

268 stimate of the OR for mortality was lower in clindamycin-treated patients (0.31; 95% CI, .09-1.12) an

269 Clindamycin-treated patients had more severe disease tha

270 iota to be normalized after ciprofloxacin or clindamycin treatment differed for various bacterial spe

271 the intestinal microbiota of mice following clindamycin treatment in the presence or absence of C. d

272 Our data suggest that clindamycin treatment of patients with severe iGAS infec

273 ble for recrudescence following fosmidomycin-clindamycin treatment.

274 rticipants were randomly assigned to receive clindamycin, trimethoprim-sulfamethoxazole (TMP-SMX), or

275 CA-MRSA is usually susceptible to clindamycin, trimethoprim-sulfamethoxazole, and rifampin

276 l MRSA isolates were susceptible in vitro to clindamycin, trimethoprim-sulfamethoxazole, and rifampin

277 reated patients had more severe disease than clindamycin-untreated patients but lower mortality (15%

278 ients (0.12; 95% CI, .01-1.29) compared with clindamycin-untreated patients.

279 romycin-resistant isolates were resistant to clindamycin upon induction with erythromycin and had the

280 ve risk, 2.1 [CI, 1.2 to 3.7]; P = 0.007) or clindamycin use (relative risk, 2.1 [1.2 to 3.6]; P = 0.

281 emic-strain isolates and studied the role of clindamycin use in these outbreaks.

282 eas all mefE(+) isolates were susceptible to clindamycin using the 2-microgram disk.

283 vancomycin, amphotericin B, ceftazidime, and clindamycin (VACC) plates.

284 in E. coli) with erythromycin, azithromycin, clindamycin, virginiamycin S, and telithromycin bound ex

285 Combination therapy with vancomycin and clindamycin was associated with decreased hospital LOS f

286 Treatment of the SSTI with clindamycin was associated with earlier clearance (hazar

287 Since frequent use of clindamycin was associated with the outbreak in one of t

288 Screening for resistance to erythromycin and clindamycin was initially accomplished with use of the K

289 esistance to tetracycline, erythromycin, and clindamycin was seen in 11% (n = 8), 5.8% (n = 20), and

290 Clindamycin was the most active antibiotic against S. co

291 P<0.001), whereas the rate of resistance to clindamycin was the same in the two groups (79 percent).

292 alosporin, aminoglycoside in combination, or clindamycin, was most often selected for empirical thera

293 o antibiotics, particularly erythromycin and clindamycin, was studied.

294 onotherapy or vancomycin in combination with clindamycin were included.

295 (SC-236) NSAIDs +/- antibiotics (penicillin, clindamycin) were given to mice challenged intramuscular

296 ylococcus aureus (MRSA) to ciprofloxacin and clindamycin (which has a similar mode of action to macro

297 In contrast, clindamycin, which is often used in patients with penici

298 , 39 demonstrated constitutive resistance to clindamycin, while 33 showed inducible resistance by dis

299 ance were noted for ampicillin-sulbactam and clindamycin, while significant decreases in resistance w

300 and clindamycin disks; the flattening of the clindamycin zone adjacent to the erythromycin disk indic